Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18668987 | TRANSMEMBRANE PORE CONSISTING OF TWO CSGG PORES | May 2024 | March 2026 | Allow | 22 | 1 | 1 | No | No |
| 18622489 | MOLECULAR GENETIC APPROACH TO TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG DEPENDENCE | March 2024 | January 2025 | Allow | 10 | 1 | 0 | No | No |
| 18518055 | CONSENSUS CODING SEQUENCES OF HUMAN BREAST AND COLORECTAL CANCER | November 2023 | April 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18297261 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | April 2023 | February 2026 | Abandon | 34 | 1 | 1 | No | No |
| 18131678 | KIT FOR IDENTIFYING MALIGNANCY, AND USES THEREOF | April 2023 | September 2024 | Allow | 17 | 0 | 0 | No | No |
| 18107477 | BIOMARKERS FOR USE IN PROGNOSIS OF MORTALITY IN CRITICALLY ILL PATIENTS | February 2023 | December 2025 | Abandon | 34 | 1 | 1 | No | No |
| 18164175 | MOLECULAR GENETIC APPROACH TO TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG DEPENDENCE | February 2023 | December 2024 | Allow | 22 | 1 | 0 | No | No |
| 18005380 | WHOLE BACTERIA CAPSULE, PREPARATION METHOD THEREFOR AND USE THEREOF | January 2023 | March 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17999326 | FIELD METHOD FOR DETECTING THE PRESENCE AND MULTI-RESISTANCE OF A PEST, IN PARTICULAR ZYMOSEPTORIA TRITICI, IN CEREAL CROPS | December 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18147134 | Method of Determining Acute Myeloid Leukemia Response to Treatment With Farnesyltransferase Inhibitors | December 2022 | December 2024 | Allow | 23 | 1 | 0 | No | No |
| 18011569 | Bone Morphogenetic Protein-8B (BMP8B) as marker and therapeutic target for liver fibrosis or liver cancer | December 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18063931 | DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE BASED ON GENES | December 2022 | October 2025 | Allow | 34 | 2 | 0 | Yes | No |
| 18078615 | PREDICTIVE BIOMARKERS FOR ONVANSERTIB TREATMENT | December 2022 | January 2026 | Allow | 38 | 1 | 1 | No | No |
| 18057614 | APTAMERS FOR THE REVERSIBLE INHIBITION OF DNA POLYMERASES | November 2022 | November 2025 | Allow | 36 | 0 | 1 | Yes | No |
| 17924352 | TREATMENT OF RETINITIS PIGMENTOSA USING IMPROVED ENGINEERED MEGANUCLEASES | November 2022 | December 2025 | Allow | 37 | 0 | 1 | Yes | No |
| 17919786 | CASY PROGRAMMABLE NUCLEASES AND RNA COMPONENT SYSTEMS | October 2022 | December 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17931205 | Non-Invasive Gene Mutation Detection in Lung Cancer Patients | September 2022 | February 2026 | Allow | 41 | 3 | 0 | No | No |
| 17892819 | METHOD FOR DIRECT MICROBIAL IDENTIFICATION | August 2022 | February 2026 | Allow | 42 | 3 | 1 | No | No |
| 17886809 | STROMAL GENE SIGNATURES FOR DIAGNOSIS AND USE IN IMMUNOTHERAPY | August 2022 | October 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17819051 | DEVICES, METHODS AND COMPOSITIONS FOR APTAMER SCREENING | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17798241 | LAMC2-NR6A1 Splicing Variant and Translation Product Thereof | August 2022 | December 2025 | Allow | 40 | 1 | 1 | No | No |
| 17883223 | DIAGNOSTIC TEST FOR PREDICTING METASTASIS AND RECURRENCE IN CUTANEOUS MELANOMA | August 2022 | March 2025 | Allow | 31 | 2 | 0 | No | No |
| 17880952 | Detection of Viral Nucleic Acid and Its Variant Using Nanopore | August 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17815647 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF LYMPHATIC SYSTEM DISORDERS | July 2022 | August 2025 | Allow | 37 | 2 | 1 | No | No |
| 17815008 | METHODS FOR COLON CANCER DETECTION AND TREATMENT | July 2022 | January 2025 | Allow | 30 | 1 | 0 | No | No |
| 17815102 | METHODS FOR PROSTATE CANCER DETECTION AND TREATMENT | July 2022 | May 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17791764 | COMPOSITION FOR PREVENTING OR TREATING DISEASE CAUSED BY MUSCLE LOSS, COMPRISING AGENT INHIBITING PHF20 | July 2022 | November 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17788852 | Liquid Biopsy Method with Measuring Autofluorescence of Nucleosomes Fragmented and Released into blood from Cell Apoptosis | June 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17842282 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | June 2022 | March 2025 | Allow | 33 | 2 | 0 | No | No |
| 17831814 | TERT PROMOTER MUTATIONS IN CANCER | June 2022 | April 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17829859 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | June 2022 | November 2024 | Allow | 30 | 1 | 0 | No | No |
| 17826818 | BCR-ABL TRUNCATION MUTATIONS | May 2022 | May 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17738499 | METHODS AND COMPOSITIONS FOR DIAGNOSING, PROGNOSING, AND TREATING ENDOMETRIOSIS | May 2022 | May 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17659641 | MOLECULAR GENETIC APPROACH TO TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG DEPENDENCE | April 2022 | August 2024 | Allow | 28 | 1 | 0 | No | No |
| 17708909 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | March 2022 | January 2025 | Allow | 34 | 2 | 0 | Yes | No |
| 17705000 | DNAZYMES FOR DETECTING LEGIONELLA PNEUMOPHILA | March 2022 | February 2026 | Allow | 47 | 1 | 1 | No | No |
| 17692408 | METHODS AND SYSTEMS FOR PREDICTING ALLERGIC RESPONSE | March 2022 | August 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17642104 | METHOD FOR DETERMINING GLOBAL BISULFITE CONVERSION EFFICIENCY | March 2022 | April 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17679073 | COMPOSITIONS AND METHODS FOR INHIBITING HEDGEHOG PATHWAY | February 2022 | February 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17616996 | METHOD FOR DETECTING SMN GENE COPY NUMBER USING SMNP AS REFERENCE | December 2021 | February 2026 | Abandon | 50 | 2 | 1 | No | No |
| 17534177 | ASSESSMENT OF MUTATION BURDEN IN SKIN | November 2021 | November 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17606232 | BLOOD BIOMARKER AND GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | October 2021 | February 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17469800 | ASSESSING RISK OF READING AND LANGUAGE IMPAIRMENT | September 2021 | November 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17399831 | BTK MUTATION AND IBRUTINIB RESISTANCE | August 2021 | June 2025 | Allow | 46 | 3 | 0 | Yes | No |
| 17392098 | VARIANTS OF TNFSF15 AND DCR3 ASSOCIATED WITH CROHN'S DISEASE | August 2021 | December 2024 | Allow | 41 | 2 | 1 | No | No |
| 17386451 | NOVEL METHOD OF COMBINED MOLECULAR CLAMPING AND ALLELE SPECIFIC qPCR TECHNOLOGY FOR KRAS G12C MUTATION DETECTION | July 2021 | October 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17350833 | COMPOSITIONS AND METHODS FOR SCREENING AND DIAGNOSIS OF PROSTATE CANCER | June 2021 | August 2024 | Allow | 38 | 2 | 1 | No | No |
| 17343285 | BLOOD BIOMARKERS FOR APPENDICITIS AND DIAGNOSTICS METHODS USING BIOMARKERS | June 2021 | June 2024 | Allow | 36 | 1 | 1 | No | No |
| 17338774 | Assays for the Detection of SARS-Co V-2 Mutants | June 2021 | May 2025 | Allow | 48 | 3 | 1 | No | No |
| 17335327 | URINE BIOMARKERS FOR DETECTING GRAFT REJECTION | June 2021 | August 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 17327100 | Diagnostic Tools and Treatments for Clear Cell Renal Cell Carcinoma | May 2021 | December 2024 | Allow | 43 | 1 | 1 | No | No |
| 17290759 | METHODS AND GENOMIC CLASSIFIERS FOR PROGNOSIS OF BREAST CANCER AND PREDICTING BENEFIT FROM ADJUVANT RADIOTHERAPY | May 2021 | September 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17162476 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES | January 2021 | October 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17262471 | USE OF METASTASES-SPECIFIC SIGNATURES FOR TREATMENT OF CANCER | January 2021 | May 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17262175 | GENE SIGNATURES FOR PREDICTING METASTASIS OF MELANOMA AND PATIENT PROGNOSIS | January 2021 | June 2025 | Allow | 52 | 3 | 2 | No | No |
| 17154781 | ASSAY FOR DETECTION OF PATHOGENIC LEPTOSPIRA STRAINS | January 2021 | March 2025 | Allow | 50 | 4 | 1 | No | No |
| 17145681 | Genetic Predictors of a Response to Treatment with CRHR1 Antagonists | January 2021 | February 2026 | Allow | 60 | 4 | 1 | No | No |
| 17145776 | Method of Treatment Using Genetic Predictors of a Response to Treatment with CRHR1 Antagonists | January 2021 | February 2026 | Allow | 60 | 4 | 1 | No | No |
| 17136793 | METHOD OF DETECTING RNA | December 2020 | September 2024 | Allow | 45 | 4 | 1 | Yes | No |
| 17255657 | EPIGENETIC METHOD TO DETECT AND DISTINGUISH IPEX AND IPEX-LIKE SYNDROMES, IN PARTICULAR IN NEWBORNS | December 2020 | December 2024 | Allow | 47 | 3 | 0 | No | No |
| 17253363 | PREDICTIVE AND PROGNOSTIC USE OF A miRNA FOR HIGH GRADE SEROUS OVARIAN CARCINOMA THERAPEUTIC CARE | December 2020 | January 2025 | Allow | 49 | 3 | 2 | No | No |
| 17118909 | BIOMARKER FOR DETERMINING AGING, DETERMINING OBESITY AND DIAGNOSING CANCER AND DIAGNOSTIC KIT USING THE SAME | December 2020 | November 2024 | Abandon | 47 | 3 | 0 | No | No |
| 15734938 | NOVEL METHOD FOR STABILIZING NUCLEIC ACID NANOSTRUCTURES | December 2020 | February 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 15734910 | METHODS FOR DETECTING ANTIVIRAL-DRUG RESISTANT VIRUS | December 2020 | December 2024 | Allow | 48 | 2 | 1 | No | No |
| 17054268 | CXCR3 AS EPIGENETIC MARKER FOR THE IDENTIFICATION OF INFLAMMATORY IMMUNE CELLS, IN PARTICULAR CD8+ MEMORY T CELLS | November 2020 | January 2025 | Allow | 51 | 2 | 1 | No | No |
| 17050285 | CIRCULAR RNAS FOR THE DIAGNOSIS AND TREATMENT OF BRAIN DISORDERS | October 2020 | December 2024 | Abandon | 50 | 1 | 1 | No | No |
| 17061013 | METHYLATION MARKERS AND TARGETED METHYLATION PROBE PANEL | October 2020 | April 2025 | Allow | 55 | 6 | 1 | Yes | Yes |
| 17016691 | METHOD FOR CONFIRMING INTRODUCTION OF FOREIGN GENE INTO CELLS AND METHOD FOR MANUFACTURING INTRODUCTION FOREIGN GENE INTO CELLS | September 2020 | February 2025 | Allow | 53 | 5 | 1 | No | No |
| 17003544 | METHODS OF PERFORMING GUIDE-SEQ ON PRIMARY HUMAN T CELLS | August 2020 | March 2025 | Allow | 54 | 2 | 0 | Yes | Yes |
| 16969172 | METHOD OF PREDICTING RESPONSE TO THERAPY BY ASSESSING TUMOR GENETIC HETEROGENEITY | August 2020 | August 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16932227 | COMPOSITIONS AND METHODS FOR INDIVIDUALIZED CHARACTERIZATION OF NON-IGE MEDIATED FOOD ALLERGIES | July 2020 | January 2026 | Allow | 60 | 4 | 1 | Yes | No |
| 16915173 | Processes and Compositions for Methylation-Based Enrichment of Fetal Nucleic Acid From a Maternal Sample Useful for Non-Invasive Prenatal Diagnoses | June 2020 | December 2024 | Abandon | 54 | 2 | 1 | No | No |
| 16760522 | CANCER DETECTION, CLASSIFICATION, PROGNOSTICATION, THERAPY PREDICTION AND THERAPY MONITORING USING METHYLOME ANALYSIS | April 2020 | May 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16821863 | Processes and Compositions for Methylation-Based Enrichment of Fetal Nucleic Acid From a Maternal Sample Useful for Non-Invasive Prenatal Diagnoses | March 2020 | March 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16800390 | METHODS FOR DIAGNOSING AND TREATING EOSINOPHILIC GASTRITIS | February 2020 | December 2024 | Allow | 57 | 4 | 2 | No | No |
| 16778618 | METHOD OF DETECTING NUCLEIC ACID AND DETECTION REAGENT | January 2020 | August 2024 | Allow | 54 | 4 | 0 | Yes | No |
| 16606928 | IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis | October 2019 | March 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16604651 | TUMOR SIGNATURE FOR METASTASIS, COMPOSITIONS OF MATTER METHODS OF USE THEREOF | October 2019 | March 2026 | Abandon | 60 | 6 | 2 | No | No |
| 16523008 | ncRNA AND USES THEREOF | July 2019 | November 2024 | Allow | 60 | 3 | 1 | No | No |
| 16439027 | PREDICTION OF POOR RESPONSE TO NEOADJUVANT CHEMORADIATION IN RECTAL CANCER PATIENTS USING A DNA REPAIR SCORE | June 2019 | September 2025 | Allow | 60 | 7 | 1 | Yes | No |
| 16335134 | MIRNAS AS NON-INVASIVE BIOMARKERS FOR BREAST CANCER | March 2019 | November 2024 | Abandon | 60 | 5 | 1 | No | No |
| 16293415 | ECTOPIC PREGNANCY KITS AND METHODS | March 2019 | July 2025 | Allow | 60 | 4 | 2 | Yes | No |
| 16328548 | NUCLEIC ACID AMPLIFICATION ASSAYS FOR DETECTION OF PATHOGENS | February 2019 | September 2024 | Allow | 60 | 4 | 1 | No | No |
| 16318720 | IDENTIFICATION OF NOVEL LOCI IN ASTHMA AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF ASTHMA | January 2019 | September 2025 | Allow | 60 | 6 | 1 | No | No |
| 16311001 | METHODS OF TREATING DRY EYE DISEASE USING TNF ALPHA ANTAGONISTS | December 2018 | January 2023 | Allow | 49 | 5 | 1 | Yes | No |
| 16303345 | METHODS AND SYSTEMS USING C4 GENE COPY NUMBER AND CELL-BOUND COMPLEMENT ACTIVATION PRODUCTS FOR IDENTIFICATION OF LUPUS AND PRE-LUPUS | November 2018 | August 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16072708 | RENAL FUNCTION EVALUATING DEVICE, DEVICE FOR PREDICTING ONSET OF KIDNEY DISEASE COMPLICATIONS, AND PHOSPHOROUS INGESTION AMOUNT ESTIMATING DEVICE | October 2018 | November 2024 | Abandon | 60 | 1 | 2 | Yes | No |
| 15014074 | PROGNOSTIC METHODS, COMPOSITIONS AND KITS FOR PREDICTION OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) RELAPSE | February 2016 | September 2019 | Allow | 43 | 2 | 1 | Yes | No |
| 14767116 | USE OF GLYCANS AND GLYCOSYLTRANSFERASES FOR DIAGNOSING/MONITORING INFLAMMATORY BOWEL DISEASE | December 2015 | December 2019 | Allow | 60 | 3 | 1 | Yes | No |
| 14858666 | MUTATION WITHIN THE CONNEXIN 26 GENE RESPONSIBLE FOR PRELINGUAL NON-SYNDROMIC DEAFNESS AND METHOD OF DETECTION | September 2015 | September 2017 | Allow | 24 | 2 | 0 | Yes | No |
| 14838945 | SERINE PROTEASES AS BIOMARKERS FOR OVARIAN CANCER | August 2015 | January 2020 | Allow | 52 | 3 | 1 | No | No |
| 14738757 | Methods of Subtyping CRC and their Association with Treatment of Colon Cancer Patients with Oxaliplatin | June 2015 | August 2018 | Allow | 38 | 1 | 1 | Yes | No |
| 14646774 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING GASTRIC CANCER | May 2015 | December 2019 | Allow | 55 | 1 | 2 | No | No |
| 14263064 | SPINOCEREBELLAR ATAXIA TYPE 8 AND METHODS OF DETECTION | April 2014 | September 2016 | Allow | 28 | 2 | 0 | Yes | No |
| 14207682 | MATERIALS AND METHODS FOR ASSESSMENT OF COLORECTAL ADENOMA | March 2014 | January 2018 | Allow | 46 | 3 | 1 | No | No |
| 14099718 | METHODS OF IDENTIFYING INDIVIDUALS AT RISK OF PERIOPERATIVE BLEEDING, RENAL DYSFUNCTION OR STROKE | December 2013 | September 2016 | Allow | 33 | 2 | 1 | Yes | No |
| 14116355 | GENOMIC MARKERS FOR PREDICTION OF LONG-TERM RESPONSE TO 2 YEARS OF GROWTH HORMONE (GH) THERAPY | November 2013 | September 2015 | Allow | 23 | 0 | 1 | Yes | No |
| 14074289 | METHODS AND COMPOSITIONS FOR PREDICTING DRUG RESPONSES | November 2013 | March 2015 | Allow | 16 | 1 | 0 | Yes | No |
| 14069815 | METHOD OF DIAGNOSING LARGE GRANULAR LYMPHOCYTE LEUKEMIA USING ALTERNATIVE SPLICE VARIANTS OF SERINE PROTEASES | November 2013 | April 2016 | Allow | 29 | 1 | 1 | Yes | No |
| 13978360 | Method of Predicting Responsiveness of B Cell Lineage Malignancies to Active Immunotherapy | September 2013 | November 2016 | Allow | 41 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SITTON, JEHANNE SOUAYA.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 44.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SITTON, JEHANNE SOUAYA works in Art Unit 1682 and has examined 150 patent applications in our dataset. With an allowance rate of 88.0%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.
Examiner SITTON, JEHANNE SOUAYA's allowance rate of 88.0% places them in the 68% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by SITTON, JEHANNE SOUAYA receive 2.49 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SITTON, JEHANNE SOUAYA is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +19.2% benefit to allowance rate for applications examined by SITTON, JEHANNE SOUAYA. This interview benefit is in the 62% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 25.8% of applications are subsequently allowed. This success rate is in the 41% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 54.6% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 62.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 69.2% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 24.7% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.5% of allowed cases (in the 65% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.